Hostname: page-component-7b7567c8c-tnkh4 Total loading time: 0 Render date: 2026-11-19T00:09:09.233Z Has data issue: false hasContentIssue false

Psychiatric side effects of interferon-β in multiple sclerosis

Published online by Cambridge University Press:  16 April 2020

J.-L. Goeb*
Affiliation:
Service de Psychiatrie de l'Enfant et de l'Adolescent, CHRU, 2, avenue Oscar-Lambret, F-59037Lille, France
C. Even
Affiliation:
Clinique des Maladies Mentales et de l'Encéphale, Centre Hospitalier Sainte-Anne, Paris, France
G. Nicolas
Affiliation:
Service de Neurologie, CHU, Angers, France
B. Gohier
Affiliation:
Service de Psychiatrie, CHU, Angers, France
F. Dubas
Affiliation:
Service de Neurologie, CHU, Angers, France
J.B. Garré
Affiliation:
Service de Psychiatrie, CHU, Angers, France
*
*Corresponding author. E-mail address: jlgoeb@wanadoo.fr (J.-L. Goeb).
Get access

Abstract

Psychiatric disorders, especially depression, are frequent in patients with multiple sclerosis (MS). They are attributed both to the psychosocial impact of a chronic, usually progressive, disabling illness and to cerebral demyelination. Besides, drugs such as corticosteroids and possibly interferon (IFN) may also have depressogenic effects. Major depressive disorders and/or suicidal ideation are a major concern and efforts to identify and minimize these reactions are of much importance. Psychiatric side effects, particularly depression, are widely reported with IFN-α and have been suspected with IFN-β but are not yet fully established. Our review of the literature revealed that most studies discard an association between IFN-β and depression or suicide. However, few patients, especially those with a history of depression, might be at higher risk for depression when treated with IFN-β. Overall, considering the uncertainty of a link between IFN-β and depression and/or suicide, as well as the complete remission of psychiatric complications after IFN discontinuation and/or antidepressant treatment, physicians should closely monitor the psychiatric status of patients, but should not refrain from including them in IFN-β treatment programs, even when they have past or present depression.

Information

Type
Review
Copyright
Copyright © European Psychiatric Association 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

Submit a response

Comments

No Comments have been published for this article.